AKT1 and cancer: The key driving pathways of CSCs, such as the PI3K/AKT/mTOR and JAK/STAT3 signals, were found to be significantly increased in cancers with high CSC properties, and hence investigations of many small molecules targeting such pathways are ongoing in clinical trials [6,7].